EcoR1 Capital’s IGM Biosciences IGMS Stock Holding History

EcoR1 Capital’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-298,597	Closed	-$7.98M	–	86
2022 Q1	$7.98M	Buy	+298,597	New	+$5.56M	0.25%	46
2021 Q4	–	Sell	-38,030	Closed	-$2.5M	–	82
2021 Q3	$2.5M	Hold	38,030	–	–	0.09%	49
2021 Q2	$3.16M	Buy	+38,030	New	+$2.82M	0.12%	47
2020 Q1	–	Sell	-100,000	Closed	-$3.82M	–	56
2019 Q4	$3.82M	Hold	100,000	–	–	0.34%	39
2019 Q3	$1.77M	Buy	+100,000	New	+$2.02M	0.22%	32

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

EcoR1 Capital's IGMS Position: Q2 2022 in Review

EcoR1 Capital sold out of IGM Biosciences (IGMS) in Q2 2022, closing a stake of 298,597 shares — an estimated $7.98M sold.

EcoR1 Capital first reported a position in IGMS in Q3 2019 and held it in 5 quarters. The position peaked at $7.98M in Q1 2022. 89 funds tracked by Wall St. Rank hold IGMS as of Q2 2022.

EcoR1 Capital reported no remaining IGM Biosciences position as of Q2 2022 after selling out during the quarter.
EcoR1 Capital sold 298,597 IGM Biosciences shares in Q2 2022, an estimated $7.98M.
EcoR1 Capital first reported a position in IGM Biosciences in Q3 2019 and held it in 5 quarters.
EcoR1 Capital's IGM Biosciences position peaked at $7.98M in Q1 2022.
89 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2022.

Based on EcoR1 Capital's 13F filing for Q2 2022, filed 15 Aug 2022.